SOVREMENNOE LEChENIE OSTEOARTROZA
- Authors: Alekseeva L.I.1
-
Affiliations:
- Issue: No 2s (2012)
- Pages: 22-27
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279262
- ID: 279262
Cite item
Open Access
Access granted
Abstract
Osteoarthrosis is the most common chronic disease of the joints. The pain and deterioration of joint function are main manifestations of osteoarthrosis, requiring their treatment. Currently, non-steroidal anti-inflammatory drugs, opioid analgesics, glucosamine and chondroitin sulfate, and application of unsaponifiable compounds of avocado and soybean are used for the treatment. The possibility of therapy with antiosteoporotic drugs, such as bisphosphonates, calcitonin, strontium ranelate, is discussed.
Full Text
References
- Datamonitor stakeholder Insight: osteoarthritis. Dec 2009 - seven major markets.Datamonitor pipeline and commercial insight: Osteoporosis, Publication date 07/2009.
- Gore M., Sadosky A., Tai K-S., et al. Clinical comorbidities, pain-related pharmacotherapy and direct medical costs of patients with osteoarthritis in clinical practice. Osteoarthritis Cartilage 2010; 18(2). Abst #281(S126).
- Beadle C., Howie C.R., Nuki G., et al. OARSI Recommendations for the management of hip and knee osteoarthritis: which treatments are being used? Audit of patients coming to arthroplasty in Scotland. Osteoarthritis Cartilage 2010; 18(2): S45-S256, abst # 343.
- Zhang W., Nuki G., Moskowitz R., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18(4): 476-99.
- Zhang W., Moskowitz R.W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-62.
- Christensen R., Astrup A., Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage 2005; 13: 20-27.
- Richette P.J., Pointou C., Garnero P. Beneficial effects of massive weight loss on symptoms, joint biomarkers and systemic inflammation in obese patients with knee osteoarthritis. Ann Rheum Dis 2011; 70: 139-44.
- Anandacoomarasamy A.J., Leibman S., Smith G. Weight loss in obese people has structure-modifying effects on knee articular cartilage. EULAR 2010; Rome, Italy; June 16-19, 2010. Abstr 0P0159.
- Lin J., Zhang W., Jones A., Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomized controlled trials. BMJ 2004; 329: 324-26.
- Avouac J., Gossec L., Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007; 15: 957-65.
- de Craen A.J., Di Giulio G., Lampe-Schoenmaeckers JE., et al. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996; 313: 321-25.
- Christensen R., Bartels E.M., Astrup A., Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16: 399-408.
- Divine J.G., Zazulak B.T., Hewett T.E. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res 2007; 455: 113-22.
- Chevalier X., Jerosch J., Goupille P. et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 2010; 69: 113-19.
Supplementary files
